

April 21, 2025  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

## Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company's Directors

Symbio Pharmaceuticals Limited (“the Company”) today announced the following details regarding the issuance of stock acquisition rights to the Company’s Directors (the 63rd Series Symbio Stock Options) pursuant to the resolution approved at the Board of Directors’ meeting held on March 25, 2025. The issuance of the stock acquisition rights does not constitute a favorable issuance.

1. Number of stock acquisition rights  
8,272 units (in total for 7 directors)
2. Class and number of shares to be issued upon exercise of the stock acquisition rights  
The Company’s common stock: 206,800 shares
3. Amount to be paid for the stock acquisition rights and calculation method
  - (1) Amount to be paid per unit: 3,900 yen
  - (2) Amount to be paid per share: 156 yen

As the amount to be paid for the stock acquisition rights is provided to the recipient in lieu of compensation, each recipient is required to waive his or her claim to the corresponding amount of compensation against the Company.

(Note)

For further information regarding the stock acquisition rights, please refer to the Company’s press release dated March 25, 2025 titled “Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors.”

### [Contact]

Investor Relations

Tel: +81(0)3 5472 1125